Where can I buy shares of jagx?
Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What's happening with jaguar health's stock?
Jaguar Health's stock price gains accelerated in recent days, following the company's announcement on Jan. 6 that it began a 28-day preclinical toxicology and safety study in dogs for lechlemer, a plant-based drug candidate for the relief of diarrhea from cholera.
Should you buy jagx stock now that Crofelemer is approved?
Meanwhile, the attempt to get crofelemer approved as a treatment for long-term Covid-19 symptoms gives traders another reason to remain interested in JAGX stock. That said, the stock probably isn’t appropriate for most investors. Given the company’s operating losses, it will likely have to raise more money.
Will jagx outperform or underperform the S&P 500 over the long term?
Vote “Outperform” if you believe JAGX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe JAGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Should I buy or sell Jaguar Health stock right now?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last twelve months. There are currently 1 buy rating...
What is Jaguar Health's stock price forecast for 2022?
1 brokers have issued 1-year price targets for Jaguar Health's stock. Their JAGX stock forecasts range from $5.00 to $5.00. On average, they expect...
How has Jaguar Health's stock price performed in 2022?
Jaguar Health's stock was trading at $1.04 at the start of the year. Since then, JAGX stock has decreased by 67.2% and is now trading at $0.3412....
When is Jaguar Health's next earnings date?
Jaguar Health is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for Jaguar...
How were Jaguar Health's earnings last quarter?
Jaguar Health, Inc. (NASDAQ:JAGX) issued its quarterly earnings data on Tuesday, May, 10th. The biotechnology company reported ($0.40) earnings per...
When did Jaguar Health's stock split? How did Jaguar Health's stock split work?
Shares of Jaguar Health reverse split on the morning of Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September...
Who are Jaguar Health's key executives?
Jaguar Health's management team includes the following people: Ms. Lisa A. Conte , Founder, CEO, Pres & Director (Age 63, Pay $722.54k) Mr. Jona...
Who are some of Jaguar Health's key competitors?
Some companies that are related to Jaguar Health include Greenwich LifeSciences (GLSI) , Evelo Biosciences (EVLO) , Daré Bioscience (DARE) , Sa...
What other stocks do shareholders of Jaguar Health own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC) , Sorr...
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs
Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency
In December of 2021, FDA conditionally approved Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea in dogs, and the company expects Canalevia could receive FDA conditional approval, under the name Canalevia™-CA2, for treatment of EID in dogsSAN FRANCISCO, CA / ACCESSWIRE / February 16, 2022 / Jaguar Health, Inc.
Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
SME status is an important designation for Italy-based Napo Therapeutics' rare/orphan disease business modelSAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / February 15, 2022 / Jaguar Health (NASDAQ:JAGX) and Napo Therapeutics S., an Italian corporation established by Jaguar Health in Milan, Italy, today announced that Napo Therapeutics has been granted Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA)..
What Happened With JAGX Stock
Canalevia™ would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrheaSAN FRANCISCO, CA / ACCESSWIRE / February 10, 2022 / Jaguar Health, Inc.
Why It Matters
A 13G regulatory filing revealed that Oasis Capital holds a 9.99% stake in Jaguar Health, news that has led investors to buy JAGX stock. That the merchant bank has taken a stake in Jaguar Health is seen as a big shot in the arm for the nascent biopharma company.
About Jaguar Health
Before today’s big move higher, JAGX stock had been trending in one direction — downward. In the last 12 months, the company’s share price has declined 90%, including an 80% retrenchment over the past six months. Shares closed yesterday at 93 cents, putting them deep in penny stock territory.
Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea.
Who is the CEO of Jaguar?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Jaguar Health stock. View analyst ratings for Jaguar Health or view top-rated stocks.
What is Jaguar Animal Health's first drug candidate?
As Jaguar’s CEO, Lisa Conte, stated, this could be a huge market opportunity for the company, as many Covid-19 patients end up having long-term health problems after being infected with the disease. Conte said that:
What is Jaguar Animal Health?
Jaguar Animal Health’s first drug candidate was a product to treat diarrhea in dogs. That product hasn’t produced tangible results yet. So the firm has started working on trying to fight inflammatory diarrhea in humans. Jaguar Health is developing a drug candidate, crofelemer, for this condition.
Is Jaguar a biotech company?
At the time of its initial public offering (IPO).Jaguar Health was originally named Jaguar Animal Health Back then, it intended to be a veterinary biotech company. People are spending more and more money on their pets, so there should be a robust market for medicine for cats and dogs. Jaguar Animal Health’s first drug candidate was a product to treat diarrhea in dogs.
Is Jaguar Health going to reverse split?
Jaguar is a clinical-stage biotech company. And it has not been particularly promising, at least not until very recently. But give the company credit for continuing to try to make something happen. The royalty deal shows that Jaguar’s management team is working hard.
Is the Jacksonville Jaguars going to be a bad team in 2021?
Jaguar’s shares need to recover a lot more to make the company’s longer-term investors whole. That said, Jaguar Health may be turning the corner and its elimination of the risk of a reverse split is another step forward.
Is JAGX stock appropriate for investors?
January 22, 2021. The Jacksonville Jaguars have long been one of the worst professional sporting teams in America. They just completed another dreadful season with only one solitary win to go along with 15 losses. Unfortunately, biotech firm Jaguar Health (NASDAQ: JAGX) has had a similar level of ineptitude.
Is Jaguar Health stock up?
That said, the stock probably isn’t appropriate for most investors. Given the company’s operating losses, it will likely have to raise more money.
Is Jaguar Health a plant based drug?
Jaguar Health's stock price is up a stunning 2,062% since its lows on Nov. 16. Investors have bid up the healthcare stock after management announced its plan to develop and commercialize crofelemer, a new drug aimed at helping people with inflammatory diarrhea, including those who have recovered from COVID-19 but are still experiencing symptoms.
